Juvaris "goes virtual", as adjuvant platform and management goes to Colby
This article was originally published in Scrip
Executive Summary
Juvaris BioTherapeutics, a privately held company with vaccine technology based in Burlingame, California, has completed a licence agreement for its technology in the area of human health, after it had already licensed the same technology to Bayer for animal health in 2008. The firm will now go virtual, in order to capture the value of future efforts of the two licensees – and its CEO Grant Pickering, in addition to providing continuing oversight, will focus on being on executive-in-residence at one of its venture backers (Kleiner Caulfield & Byers).